AdaptHealth (AHCO) EBITDA (2018 - 2026)

AdaptHealth's EBITDA history runs 9 years deep, the most recent figure standing at $5.5 million for Q1 2026.

• On a quarterly basis, EBITDA fell 76.31% year-over-year to $5.5 million in Q1 2026; TTM through Mar 2026 was $73.2 million, a 69.04% decrease from a year earlier, with the FY2025 full-year figure at $90.9 million, down 65.54% from the prior year.
• EBITDA advanced to $5.5 million in Q1 2026 per AHCO's latest filing, from -$73.3 million in the prior quarter.
• Across five years, EBITDA topped out at $97.7 million in Q4 2024 and bottomed at -$461.0 million in Q3 2023.
• The 5-year median for EBITDA is $51.6 million (2022), against an average of -$2.8 million.
• Across the five-year window, EBITDA jumped 234.56% in 2022 and sank 970.72% in 2023, its largest moves.
• Year by year, EBITDA stood at $26.7 million in 2022, then slumped by 914.77% to -$217.8 million in 2023, then soared by 144.84% to $97.7 million in 2024, then slumped by 175.03% to -$73.3 million in 2025, then jumped by 107.49% to $5.5 million in 2026.
• Per Business Quant, the three latest AHCO EBITDA figures stand at $5.5 million (Q1 2026), -$73.3 million (Q4 2025), and $61.7 million (Q3 2025).